ArticleBMC neurology2026
Serial high-resolution ultrasonography demonstrates dynamic inflammatory changes during multidrug therapy in leprosy neuropathy: a longitudinal case report.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeprosy is a chronic granulomatous infection caused by Mycobacterium leprae, the leading infectious cause of nerve impairment-related disability. Peripheral neuropathy may occur before, during, or after diagnosis and treatment or as a result of leprosy reactions. High-resolution ultrasonography (HRUSG) provides a more precise evaluation of peripheral nerve abnormality in leprosy patients than clinical examination alone. Longitudinal data assessing dynamic alterations following multidrug treatment (MDT) using HRUSG are limited, especially in endemic settings. We report two leprosy patients who underwent HRUSG evaluation before and after MDT. CASE PRESENTATION: Case 1: A 20-year-old male with tuberculoid leprosy presenting with a hypoesthetic hypopigmented plaque on the left arm without palpable nerve enlargement. HRUSG performed before and three months after MDT revealed no nerve abnormalities. Case 2: A 47-year-old male with borderline lepromatous leprosy and severe reversal reaction presented with multiple hypoesthetic erythematous plaques, finger shortening, and stocking anesthesia, without palpable nerve thickening. Pre-treatment HRUSG markedly increased cross-sectional area (CSA) (e.g., ulnar nerve up to 37.0 mm²), hypoechogenicity, and hypervascularity. After two months of MDT combined with corticosteroids, CSA decreased across examined nerves (e.g., ulnar nerve to 27.2 mm²), and hypervascularity resolved in several sites, while hypoechogenicity persisted.
conclusionsThis first longitudinal HRUSG comparison of TT and BL leprosy cases in Indonesia demonstrates that serial ultrasonography can detect subclinical nerve involvement and document early structural improvement during therapy. HRUSG may serve as a non-invasive adjunct for monitoring inflammatory activity and therapeutic response in leprosy neuropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.